Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AGTINYSE:AVNSNASDAQ:EMBCNASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTIAgiliti$10.06$5.07▼$18.61$1.37B1.91.78 million shs26.51 million shsAVNSAvanos Medical$12.15+0.5%$12.46$11.84▼$25.36$561.63M1.14375,706 shs1.07 million shsEMBCEmbecta$9.77+0.3%$11.21$9.49▼$21.48$570.96M1.13484,903 shs1.27 million shsTNGXTango Therapeutics$5.16+7.5%$2.37$1.03▼$12.02$559.29M1.241.50 million shs4.98 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTIAgiliti0.00%0.00%0.00%0.00%0.00%AVNSAvanos Medical0.00%+0.29%-1.38%-15.70%-37.91%EMBCEmbecta0.00%+2.20%-8.86%-24.03%-21.90%TNGXTango Therapeutics0.00%+10.02%+180.43%+196.55%-48.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTIAgilitiN/AN/AN/AN/AN/AN/AN/AN/AAVNSAvanos Medical2.2964 of 5 stars0.03.00.00.02.61.72.5EMBCEmbecta4.1208 of 5 stars3.21.03.30.00.53.33.8TNGXTango Therapeutics1.9576 of 5 stars3.51.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTIAgiliti 0.00N/AN/AN/AAVNSAvanos Medical 0.00N/AN/AN/AEMBCEmbecta 2.33Hold$19.3397.88% UpsideTNGXTango Therapeutics 3.00Buy$12.20136.43% UpsideCurrent Analyst Ratings BreakdownLatest AGTI, TNGX, AVNS, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.004/14/2025TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTIAgiliti$1.17B0.00N/A5.76$6.98 per share0.00AVNSAvanos Medical$689.20M0.81$11.91 per share1.02$18.03 per share0.67EMBCEmbecta$1.12B0.51$3.33 per share2.93($12.80) per share-0.76TNGXTango Therapeutics$42.07M13.29N/AN/A$1.86 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTIAgiliti-$19.42M-$0.14N/A0.00N/A-1.65%6.47%2.53%N/AAVNSAvanos Medical-$392.10M-$8.37N/A7.02N/A-55.80%6.26%4.63%7/30/2025 (Estimated)EMBCEmbecta$78.30M$0.9010.863.180.624.89%-19.67%12.27%8/8/2025 (Estimated)TNGXTango Therapeutics-$130.30M-$1.22N/AN/AN/A-322.67%-62.75%-39.94%8/6/2025 (Estimated)Latest AGTI, TNGX, AVNS, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNGXTango Therapeutics-$0.34-$0.36-$0.02-$0.36$6.73 million$5.39 million5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/6/2025Q1 2025AVNSAvanos Medical$0.19$0.26+$0.07$0.14$161.75 million$167.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTIAgilitiN/AN/AN/AN/AN/AAVNSAvanos MedicalN/AN/AN/AN/AN/AEMBCEmbecta$0.606.14%N/A66.67%N/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ALatest AGTI, TNGX, AVNS, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTIAgiliti1.131.721.34AVNSAvanos Medical0.122.571.56EMBCEmbectaN/A2.481.83TNGXTango TherapeuticsN/A6.266.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTIAgiliti99.12%AVNSAvanos Medical95.17%EMBCEmbecta93.83%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipAGTIAgiliti4.16%AVNSAvanos Medical2.64%EMBCEmbecta0.42%TNGXTango Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGTIAgiliti5,800136.08 million130.42 millionOptionableAVNSAvanos Medical2,22746.24 million45.02 millionOptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableTNGXTango Therapeutics90108.39 million100.26 millionOptionableAGTI, TNGX, AVNS, and EMBC HeadlinesRecent News About These CompaniesTango Therapeutics (NASDAQ:TNGX) Shares Up 4.7% - What's Next?June 17, 2025 | marketbeat.comTango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trialsJune 16, 2025 | investing.comFY2025 EPS Estimate for Tango Therapeutics Lifted by AnalystJune 14, 2025 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Shares Down 7.4% - Here's What HappenedJune 13, 2025 | marketbeat.comEquities Analysts Offer Predictions for TNGX FY2026 EarningsJune 13, 2025 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Shares Gap Down - Time to Sell?June 12, 2025 | marketbeat.comB. Riley Expects Higher Earnings for Tango TherapeuticsJune 12, 2025 | marketbeat.comCantor Fitzgerald Predicts TNGX FY2026 EarningsJune 11, 2025 | marketbeat.comQ2 Earnings Forecast for TNGX Issued By B. RileyJune 11, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Trading Up 11.8% - Should You Buy?June 10, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DEJune 9, 2025 | marketbeat.comMillennium Management LLC Invests $771,000 in Tango Therapeutics, Inc. (NASDAQ:TNGX)June 7, 2025 | marketbeat.comTango Therapeutics: PRMT5 Data Readout Due In 2025 Is CriticalJune 6, 2025 | seekingalpha.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Buy" by AnalystsJune 3, 2025 | marketbeat.comWoodline Partners LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 28, 2025 | marketbeat.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27, 2025 | finance.yahoo.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27, 2025 | globenewswire.comTango Therapeutics starts trial for brain cancer drugMay 23, 2025 | uk.investing.comTango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid TumorsMay 21, 2025 | globenewswire.comTango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target PriceMay 16, 2025 | finance.yahoo.comTango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline DevelopmentsMay 14, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGTI, TNGX, AVNS, and EMBC Company DescriptionsAgiliti NYSE:AGTIAgiliti, Inc., together with its subsidiaries, provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services that are comprehensive programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity. It also provides clinical engineering services comprising maintenance, repair, and remediation solutions for various types of medical equipment, including general biomedical equipment, diagnostic imaging equipment, and surgical equipment through supplemental and outsourced offerings. In addition, the company offers equipment solutions, which primarily provide supplemental, peak need, and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers, including premier healthcare institutions and integrated delivery networks. It serves acute care hospitals, health systems and integrated delivery networks and alternate site providers. The company was founded in 1939 and is headquartered in Eden Prairie, Minnesota. Agiliti, Inc. operates as a subsidiary of THL Agiliti LLC.Avanos Medical NYSE:AVNS$12.14 +0.07 (+0.54%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$12.14 -0.01 (-0.08%) As of 06/20/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Embecta NASDAQ:EMBC$9.77 +0.03 (+0.31%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.70 -0.07 (-0.77%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Tango Therapeutics NASDAQ:TNGX$5.16 +0.36 (+7.50%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.16 +0.00 (+0.10%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
